Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887881 | 1.00 | CTSS (0.48) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL28741504 | 0.92 | MDM4 (0.52) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL28741502 | 0.92 | MDM4 (0.52) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL29351891 | 0.91 | MDM4 (0.48) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL1957887 | 0.91 | MDM4 (0.48) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL12568249 | 0.91 | CTSS (0.52) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL7338800 | 0.91 | MDM4 (0.48) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL29633851 | 0.91 | MDM2 (0.48) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL12568250 | 0.91 | CTSS (0.52) | CTSSCTSKMDM2MDM4TP53 | |
| SCHEMBL5887493 | 0.90 | MDM2 (0.47) | MDM2MDM4TP53CASP3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | CTSS 1702/4885CTSK 2430/4885MDM2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.